Vanguard Group Inc Black Diamond Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,356,833 shares of BDTX stock, worth $5.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,356,833
Previous 2,413,941
2.37%
Holding current value
$5.19 Million
Previous $5.17 Million
29.27%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
41.1MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$22.9 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$12.3 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$9.79 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.08 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$6.01 Million0.1% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $79.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...